Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Vibrotactile Stimulation in Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02933476
Recruitment Status : Completed
First Posted : October 14, 2016
Results First Posted : January 23, 2018
Last Update Posted : January 23, 2018
Sponsor:
Collaborator:
John A Blume Foundation
Information provided by (Responsible Party):
Helen M. Bronte-Stewart, Stanford University

Brief Summary:
The purpose of this study is to examine the possibility of a new, non-invasive, non-drug treatment for Parkinson's disease. The treatment involves gentle vibratory stimulation delivered to the fingertips (called 'vibrotactile stimulation'). Along with the treatment, participants will also undergo kinematic testing.

Condition or disease Intervention/treatment Phase
Parkinson's Disease Device: Vibrotactile Stimulation Not Applicable

Detailed Description:
Patient will be phone screened and/or have a physical and neurological examination to determine if it is appropriate for them to participate in this study. This testing includes the Unified Parkinson's Disease Rating Scale, Part III (UPDRS III). Research assistants will explain the study and obtain informed consent. There will be three consecutive days of testing, as well as 2 follow up visits at 1 and 4 weeks. Visits include the following: Patients will have sensors put on their hands, feet, and chest. These sensors measure their movement while they perform kinematic tasks such as forward walking, wrist movements, and the UPDRS III. Patients will also be given vibrotactile stimulation for a total of 4 hours throughout the day. During this time, patients will be provided with books/movies as entertainment, and they may move around freely. Patients will also be asked to complete several questionnaires throughout the visits about their Parkinson's symptoms.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Vibrotactile Stimulation in Parkinson's Disease
Study Start Date : May 2016
Actual Primary Completion Date : November 2016
Actual Study Completion Date : November 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Vibrotactile Stimulation Treatment
All patients will receive the vibrotactile stimulation treatment. No deception will be used.
Device: Vibrotactile Stimulation
The tactile stimulator is being tested for an off-label use as treatment for Parkinson's disease. There are nodes embedded into the fingertips of gloves that gently vibrate in an alternating pattern. The sensation is similar to the feeling of a phone vibrating. This is a non-significant risk device.




Primary Outcome Measures :
  1. Number of Patients Reporting Any Adverse Effects [ Time Frame: 1 Month ]
    Questionnaire asks patients to record any adverse effects they experienced.


Secondary Outcome Measures :
  1. Unified Parkinson's Disease Rating Scale, Part III [ Time Frame: 1 Month ]
    We used the motor portion of the Unified Parkinson's disease Rating Scale (UPDRS) and excluded rigidity and speech from the assessment. Overall range of the score for the motor portion (excluding rigidity and speech) range from 0 to 108, where 0= best possible outcome and 108= worst possible outcome.

  2. Root Mean Square Velocity [ Time Frame: 1 Month ]
    Using gyroscopes to track patient movement testing, root mean square velocity (Vrms) of of the wrist during repetitive wrist flexion extension task was obtained.

  3. Gait Asymmetry [ Time Frame: 1 Month ]
    Using data collected from inertial measurement unit (IMU) sensors on subject, we were able to measure gait asymmetry. For each subject, the swing time (SW) was calculated and averaged across strides for the left and right legs (SWL and SWR). We obtained gait asymmetry using the following: 100 x /ln(SWR/SWL)/. 0 marks perfect symmetry and greater values higher asymmetry. There is no maximum limit.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age at least 18 years of age.
  2. Speaks and understands English.
  3. A diagnosis of idiopathic Parkinson's disease, Hoehn and Yahr Stage II or III
  4. Able and willing to come to study visits (3 consecutive days, as well as 2 follow up visits, at 1 and 4 weeks)
  5. Able and willing to stop therapy during the daytime for the days they come to the clinic for the study.
  6. Have improvement in motor signs ON versus OFF dopaminergic medication.
  7. If on medication, the patient should be on stable doses of Sinemet and/or Stalevo (Carbidopa/Levodopa Parkinson's medication) as part of their medicinal regimen (Patient does not need to be on medication to be included in the study).

Exclusion Criteria:

  1. Subjects, who are pregnant, are capable of becoming pregnant, or who are breast feeding.
  2. Subjects with very advanced Parkinson's disease, Hoehn and Yahr stage IV on medication (non-ambulatory).
  3. Have significant cognitive impairment and/or dementia, as determined by a neurologist at the Stanford Movement Disorders Clinic.
  4. Have an implanted electronic device such as a cardiac pacemaker/defibrillator or medication pump.
  5. Subjects who have an inability to comply with study follow-up visits.
  6. Subjects who are unable to understand or sign the informed consent.
  7. Have an MRI showing focal brain lesions that could indicate a non-idiopathic movement disorder.
  8. Have an active infection.
  9. Require diathermy, electroconvulsive therapy (ECT), or transcranial magnetic stimulation (TMS) to treat a chronic condition.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02933476


Locations
Layout table for location information
United States, California
Stanford Movement Disorders Clinic
Stanford, California, United States, 94304
Sponsors and Collaborators
Stanford University
John A Blume Foundation
Investigators
Layout table for investigator information
Principal Investigator: Helen Bronte-Stewart, MD, MS Stanford University

Publications:
Layout table for additonal information
Responsible Party: Helen M. Bronte-Stewart, Principal Investigator, Stanford University
ClinicalTrials.gov Identifier: NCT02933476    
Other Study ID Numbers: IRB 35238
First Posted: October 14, 2016    Key Record Dates
Results First Posted: January 23, 2018
Last Update Posted: January 23, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases